Literature DB >> 18451006

Who are the new users of antipsychotic medications?

Marisa Elena Domino1, Marvin S Swartz.   

Abstract

OBJECTIVE: This study examined changes in the prevalence of antipsychotic medication use and the characteristics of antipsychotic users in the U.S. population between 1996 and 2005.
METHODS: Data from the Medical Expenditure Panel Survey from 1996-1997 and 2004-2005 were used to examine the rate of first- and second-generation antipsychotic medication use and changes in the characteristics of users of all ages. Trends were examined in the level of use by antipsychotic users, both in terms of defined daily dose units and number of prescriptions.
RESULTS: The rate of antipsychotic use has increased substantially between 1996-1997 and 2004-2005, but the average dose measured both by defined daily dose units and number of prescriptions has remained constant. The rapid diffusion of antipsychotic medications did not occur among individuals with schizophrenia, but rather it included substantial growth among those with newer on-label conditions (such as bipolar disorder) and a high, constant rate of off-label use. Demographic, financial, and insurance characteristics of users have remained fairly constant, with few exceptions. The average age of antipsychotic users declined during the study period, because more children were using these medications in 2004-2005. However, the gender, racial, ethnic, and insurance composition of users has been fairly stable over time.
CONCLUSIONS: The rapid diffusion of second-generation antipsychotic medications was achieved by large increases in the rate of use in certain subpopulations, most notably youths. Increasing understanding about the marginal efficacy and side-effect risks of newer and more expensive antipsychotic agents, even when prescribed as indicated, suggests that the dramatic increase in use warrants careful attention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451006      PMCID: PMC2739805          DOI: 10.1176/ps.2008.59.5.507

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  32 in total

1.  National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

Authors:  Mark Olfson; Carlos Blanco; Linxu Liu; Carmen Moreno; Gonzalo Laje
Journal:  Arch Gen Psychiatry       Date:  2006-06

2.  Increased prescribing trends of paediatric psychotropic medications.

Authors:  I C K Wong; M L Murray; D Camilleri-Novak; P Stephens
Journal:  Arch Dis Child       Date:  2004-12       Impact factor: 3.791

3.  Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.

Authors:  Haiden A Huskamp; Judith A Shinogle
Journal:  Psychiatr Serv       Date:  2005-09       Impact factor: 3.084

4.  Prescription drugs and the changing patterns of treatment for mental disorders, 1996-2001.

Authors:  Samuel H Zuvekas
Journal:  Health Aff (Millwood)       Date:  2005 Jan-Feb       Impact factor: 6.301

Review 5.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Authors:  Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

6.  Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.

Authors:  Haiden A Huskamp
Journal:  Health Aff (Millwood)       Date:  2006 May-Jun       Impact factor: 6.301

Review 7.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

8.  Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.

Authors:  Eric Q Wu; Lizheng Shi; Howard Birnbaum; Teresa Hudson; Ronald Kessler
Journal:  Psychol Med       Date:  2006-08-15       Impact factor: 7.723

9.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Authors:  Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; T Scott Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

10.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

View more
  33 in total

1.  State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.

Authors:  Marisa Elena Domino; Christopher Alan Beadles
Journal:  Health Serv Outcomes Res Methodol       Date:  2014-06-01

2.  Ten-year trends in quality of care and spending for depression: 1996 through 2005.

Authors:  Catherine A Fullerton; Alisa B Busch; Sharon-Lise T Normand; Thomas G McGuire; Arnold M Epstein
Journal:  Arch Gen Psychiatry       Date:  2011-12

3.  Off-label use of atypical antipsychotics: cause for concern?

Authors:  Andrew McKean; Erik Monasterio
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

4.  First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Authors:  Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-05

Review 5.  Review of the operational definition for first-episode psychosis.

Authors:  Nicholas J K Breitborde; Vinod H Srihari; Scott W Woods
Journal:  Early Interv Psychiatry       Date:  2009-11       Impact factor: 2.732

6.  Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects.

Authors:  Gary Remington; Margaret Hahn
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

7.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

8.  A nearly overlooked mild case of ziprasidone-induced lingual dystonia.

Authors:  Alexander C Tsai
Journal:  J Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.153

9.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

10.  Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities.

Authors:  Leslie Miller; Mark A Riddle; David Pruitt; Al Zachik; Susan dosReis
Journal:  J Behav Health Serv Res       Date:  2013-01       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.